Beam Therapeutics (NASDAQ:BEAM – Free Report) had its target price reduced by Wedbush from $65.00 to $28.00 in a report published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.
Several other analysts have also recently issued reports on BEAM. Wall Street Zen raised shares of Beam Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Thursday, October 15th. Bank of America reissued a “buy” rating and issued a $47.00 target price on shares of Beam Therapeutics in a research note on Wednesday, July 8th. HC Wainwright restated a “buy” rating on shares of Beam Therapeutics in a report on Tuesday. Finally, William Blair upgraded Beam Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Beam Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $46.90.
Read Our Latest Research Report on BEAM
Beam Therapeutics Stock Down 5.6%
NASDAQ BEAM opened at $27.23 on Wednesday. The business has a fifty day moving average price of $25.93 and a 200 day moving average price of $28.19. Beam Therapeutics has a one year low of $20.23 and a one year high of $38.26. The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.57 and a current ratio of 14.57. The company has a market cap of $2.81 billion, a P/E ratio of -31.66 and a beta of 2.20.
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.07). The business had revenue of $0.49 million for the quarter, compared to analysts’ expectations of $16.37 million. Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%. Beam Therapeutics’s quarterly revenue was down 94.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.00) EPS. Research analysts anticipate that Beam Therapeutics will post -4.49 EPS for the current fiscal year.
Insider Activity at Beam Therapeutics
In other news, CEO John Evans sold 25,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.57, for a total transaction of $589,250.00. Following the transaction, the chief executive officer owned 1,047,205 shares of the company’s stock, valued at approximately $24,682,621.85. The trade was a 2.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.80% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Beam Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Versant Capital Management Inc increased its holdings in Beam Therapeutics by 123.6% during the 3rd quarter. Versant Capital Management Inc now owns 1,239 shares of the company’s stock worth $30,000 after purchasing an additional 685 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in Beam Therapeutics in the 2nd quarter valued at about $43,000. Hollencrest Capital Management acquired a new stake in Beam Therapeutics in the 1st quarter valued at about $43,000. Nykredit A S purchased a new position in shares of Beam Therapeutics in the 2nd quarter valued at about $75,000. Finally, Allworth Financial LP purchased a new position in shares of Beam Therapeutics in the 2nd quarter valued at about $88,000. 99.68% of the stock is currently owned by institutional investors and hedge funds.
More Beam Therapeutics News
Here are the key news stories impacting Beam Therapeutics this week:
- Positive Sentiment: Clinical optimism remains a potential support. Beam reviewed initial Phase 1/2 data for BEAM-301 in glycogen storage disease type 1a, keeping investor attention on the company’s base-editing pipeline and future milestone potential. Beam Therapeutics reviews initial BEAM-301 data
- Positive Sentiment: Citi initiated or reiterated a Buy view on Beam, while broader healthcare commentary also identified BEAM among attractive stocks. This reinforces the bullish long-term case centered on gene editing and potential pipeline catalysts. Beam Therapeutics gets a Buy from Citi
- Positive Sentiment: Shares previously gained 15.6% on above-average volume, suggesting strong short-term interest. However, the accompanying analysis cautioned that recent earnings-estimate trends may not sustain the rally. Beam Therapeutics moves 15.6% higher
- Neutral Sentiment: Beam crossed above its 200-day moving average, a potentially constructive technical signal, but the report tied the move to an analyst downgrade, limiting its significance. Beam crosses above its 200-day moving average
- Negative Sentiment: Wedbush cut its price target, adding pressure to the stock after its recent advance. The downgrade signals more cautious near-term expectations even as other analysts remain constructive. Wedbush cuts Beam Therapeutics price target
- Negative Sentiment: HC Wainwright retained a Buy rating but lowered most 2026–2029 EPS forecasts, including FY2026 to a loss of $4.67 per share and FY2027 to a loss of $5.23. The revisions highlight continued heavy losses and delayed profitability; FY2030 was modestly improved to a $1.48 loss. HC Wainwright earnings estimate revisions
Beam Therapeutics Company Profile
Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.
Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.
Read More
- Five stocks we like better than Beam Therapeutics
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
